dUTPase as a Platform for Antimalarial Drug Design: Structural Basis for the Selectivity of a Class of Nucleoside Inhibitors  by Whittingham, Jean L. et al.
Structure, Vol. 13, 329–338, February 2005, ©2005 Elsevier Ltd All rights reserved. DOI 10.1016/j.str.2004.11.015
dUTPase as a Platform for Antimalarial Drug
Design: Structural Basis for the Selectivity
of a Class of Nucleoside Inhibitors
Jean L. Whittingham,1,8 Isabel Leal,2,8
Corinne Nguyen,3 Ganasan Kasinathan,3
Emma Bell,1 Andrew F. Jones,4 Colin Berry,4
Agustin Benito,5 Johan P. Turkenburg,1
Eleanor J. Dodson,1 Luis M. Ruiz Perez,2
Anthony J. Wilkinson,1 Nils Gunnar Johansson,6
Reto Brun,7 Ian H. Gilbert,3
Dolores Gonzalez Pacanowska,2
and Keith S. Wilson1,*
1Structural Biology Laboratory
Department of Chemistry
University of York
Heslington
York YO10 5YW
United Kingdom
2Instituto de Parasitologia y Biomedicina
Consejo Superior de Investigacione Cientificas
C/Ventanilla 11
18001 Granada
Spain
3Welsh School of Pharmacy
University of Cardiff, Redwood Building
King Edward VII Avenue
Cardiff CF10 3XF
United Kingdom
4Cardiff School of Biosciences
Biomedical Building
Museum Avenue
PO Box 911
Cardiff CF10 3US
United Kingdom
5Centro Nacional de Microbiología
Instituto de Salud Carlos III
Ctra. Majadahonda-Pozuelo km 2
28220 Majadahonda
Madrid
Spain
6Medivir AB
Lunastigen 7
S-141 44 Huddinge
Sweden
7Swiss Tropical Institute
Parasite Chemotherapy
Socinstrasse 57
CH-4002 Basel
Switzerland
Summary
Pyrimidine metabolism is a major route for therapeutic
intervention against malaria. Here we report inhibition
and structural studies on the deoxyuridine nucleotido-
hydrolase from the malaria parasite Plasmodium falci-
parum (PfdUTPase). We have identified a series of triphe-
nylmethane derivatives of deoxyuridine with antimalarial*Correspondence: keith@ysbl.york.ac.uk
8 These authors contributed equally to this work.activity in vitro which inhibit specifically the Plasmo-
dium dUTPase versus the human enzyme. A 2.4 Å crys-
tal structure of PfdUTPase in complex with one of these
inhibitors reveals an atypical trimeric enzyme in which
the triphenylmethane derivative can be seen to select
for PfdUTPase by way of interactions between the trityl
group and the side chains of residues Phe46 and Ile117.
Immunofluorescence microscopy studies of parasitized
red blood cells reveal that enzyme concentrations are
highest during the trophozoite/schizont stages, sug-
gesting that PfdUTPase has a major role in DNA repli-
cation. Taken together the data show that PfdUTPase
may be considered as an antimalarial drug target.
Introduction
Malaria is a major threat to human health in large areas
of the world, with 300–500 million new clinical cases
appearing every year leading to 1.22 million deaths,
mainly of children (World Health Organization, 2003).
The principal cause of disease and death in humans is
the parasite Plasmodium falciparum, which has a com-
plex life-cycle involving insect as well as human hosts
and a series of distinct developmental stages (Miller et
al., 2002). Treatment of malaria is limited by the ab-
sence of an effective vaccine (Richie and Saul, 2002)
and the emergence of resistance to the principal drugs
that have been used to control the disease (Ridley,
2002). Hence, new antimalarial strategies are urgently
required.
The enzyme dUTPase (deoxyuridine 5#-triphosphate
nucleotido-hydrolase, E.C. 3.6.1.23) is essential in both
eukaryotes and prokaryotes (Gadsden et al., 1993; el-
Hajj et al., 1988). By catalyzing the hydrolysis of dUTP
to dUMP it supplies the dUMP substrate for dTTP syn-
thesis and, by maintaining low dUTP/dTTP ratios in
cells, minimizes uracil incorporation into DNA (Richie
and Saul, 2002). Although DNA glycosylase repair en-
zymes can excise uracil from DNA, too many repairs
destabilize the DNA framework and, in time, are fatal for
the cell. dUTPases occur in several different oligomeric
forms which are unrelated in sequence or structure:
monomeric (in herpes virus and Epstein-Barr virus), di-
meric (in trypanosomes and leishmania), and trimeric
(in mammals, Plasmodium, and various bacteria and
viruses). Crystal structures of five trimeric dUTPases
(E. coli [Cedergren-Zeppezauer et al., 1992], human
[Mol et al., 1996], equine infectious anemia virus
[Dauter et al., 1999], feline immunodeficiency virus
[Prasad et al., 1996], and M. jannaschii [Huffman et al.,
2003]) and one dimeric dUTPase (T. cruzi [Harkiolaki et
al., 2003]) have been published to date. dUTPases
within each oligomeric class have similar structures al-
though they often share only low-level pair-wise se-
quence identities.
The trimeric dUTPases possess five conserved se-
quence motifs (Figure 1). These cluster to form the sub-
strate recognition site and reaction center, bestowing
high selectivity toward dUTP to the exclusion of dCTP,
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330Figure 1. Alignment of the Sequences of Trimeric dUTPases
Known structures from: P. falciparum (P. fal), human (H. sap), equine infectious anemia virus (EIAV), feline immunodeficiency virus (FIV),
E. coli (E. coli), and M. tuberculosis (M. tub) are shown.
The sequences were initially aligned using the program ESPript (Gouet et al., 1999) and then adjusted manually in the light of structural data.
The numbering and the secondary structure elements above the alignment refer to the PfdUTPase structure. Strictly conserved residues are
highlighted in red blocks while largely conserved residues are outlined by blue boxes.dTTP, and UTP. This specificity is achieved through hy- m
cdrogen bonding patterns that favor binding of the uracil
mbase, and intimate interactions with the sugar and the
mbase that exclude the 2#-hydroxyl of a ribose sugar and
sthe 5-methyl group of thymine. Currently, known inhibi-
gtors of the enzyme are mainly confined to isosteres of
adUTP that are not suitable as drug candidates.
pPfdUTPase has relatively low sequence similarity
with its human ortholog (28.4% identity) making it a
Esuitable drug target. Indeed, this enzyme may assume
pextra significance in the parasite given the high AT:CG
vratio (approximately 80:20) in its genome. In order to
rinvestigate PfdUTPase in this capacity, the enzyme has
sbeen cloned, overexpressed, and characterized. Sev-
eral drug-like leads have been discovered through
ascreening for selective enzyme inhibitors, and these
lhave also been shown to inhibit the growth of P. falci-
mparum. The crystal structure of PfdUTPase in complex
gwith one of these inhibitors shows that inhibitor selec-
ztivity toward PfdUTPase is bestowed by way of interac-
otions between the trityl group and the side chains of
w
residues Phe46 and Ile117. This structure will provide a
2
platform for improvements in the selectivity of the in- p
hibitors through molecular modeling and synthetic s
chemistry. c
s
Results a
m
Sequence Analysis and Stage-Specific Expression s
of P. falciparum dUTPase a
The Pfdut gene is located on chromosome 11. The nu- m
cleotide sequence reveals an ORF encoding a protein s
2of 173 amino acid residues with a relative molecularass of 19573 Da and a calculated pI of 6.5. Sequence
omparisons show that PfdUTPase belongs to the tri-
eric family of dUTPases and that the five conserved
otifs characteristic of this family of proteins are pre-
ent (Figure 1). There is an insertion of 25 residues be-
inning at residue 59 which contains characteristics of
low complexity region (LCR) typical of P. falciparum
roteins (Brocchieri, 2001) (Figure 1).
Recombinant PfdUTPase was overexpressed in
. coli cells. The purified enzyme exhibited kinetic
arameters similar to other dUTPases with Vmax and KM
alues for dUTP of 25.75 mol min−1 mg−1 and 2.4 M,
espectively, and strict substrate specificity (data not
hown).
Antibodies raised against the recombinant enzyme
llowed immunofluorescence studies and intracellular
ocation analysis to be carried out. Fluorescence was
inimal in the ring stage, but as the parasite pro-
ressed into the proliferative intraerythrocytic tropho-
oite/schizont asexual stages, intensive staining was
bserved, suggesting that the enzyme is associated
ith forms undergoing active DNA replication (Figure
). In this regard, it has been previously shown that ex-
ression of genes involved in DNA replication follows a
tage-specific pattern coinciding with the beginning of
hromosomal replication 28–31 hr after merozoite inva-
ion and continuing through most of schizogeny (White
nd Kilbey, 1996; Inselburg and Banyal, 1984). Develop-
entally regulated expression of dUTPase and the as-
ociation of the enzyme with the trophozoite/schizont
sexual stages have been inferred previously from
icroarray analysis (Le Roch et al., 2003) and suppres-
ion substractive hybridization (Spielmann and Beck,
000).
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331Figure 2. Indirect Immunofluorescence Mi-
croscopy of Intraerythrocytic Stages of
P. falciparum, Using an Asynchronous Cul-
ture of the Parasite (3D7 strain) and anti-
PfdUTPase Polyclonal Antibodies
The illustration shows the results of costain-
ing with FITC (green) and propidium iodide
(red) during different stages: (A) trophozoites
and a schizont; (B) an early schizont; (C) a
late schizont with emerging merozoites.Fluorescence obtained with the labeled antibody did
not colocalize with that obtained by treating the cells
with propidium iodide (a nuclear stain), and was not
characteristic of apicoplast proteins. Rather, an extens-
ive fluorescence suggestive of occupation of the para-
sitophorous vacuole was evidenced (Figure 2). Hence,
PfdUTPase does not appear to be associated with or-
ganelles such as the nucleus of the apicoplast. In con-
trast, studies with isoforms of human dUTPase have
shown a nuclear and mitochondrial distribution in
agreement with the major role of the enzyme in DNA
replication (Ladner and Caradonna, 1997). In recent
years, many observations have indicated a number of
biologically relevant processes within the vacuole that
are important for parasite survival. It is possible that
dUTPase is secreted by the parasite in order to hy-
drolyze host/parasite dUTP to the dUMP necessary for
thymidylate biosynthesis.
Inhibition and Antiparasite Assays
Nucleoside derivatives were screened for their ability to
inhibit PfdUTPase. To evaluate selectivity, parallel as-
says using purified recombinant human dUTPase were
carried out. From these assays, the initial lead was
compound 2, which inhibited the parasite enzyme with
a Ki of 0.2 µM, compared to 46.3 µM for the human
enzyme, giving a selectivity of the order of 200-fold (Ta-
ble 1). Further compounds were then prepared to derive ing compounds 1–3 with compounds 4 and 5).
Table 1. Inhibition of P. falciparum and Human dUTPases and Activity against P. falciparum K1 Strain Cultured in Human Erythrocytes
Inhibition of the Enzyme Activity against Parasites
Human Ki L6-cells IC50
No. X Y R R1 Pf Ki (µM) (µM) Select. Pf IC50 (µM) (µM) Select.
1 O C Ph OH 1.8 17.7 9.8 6 192 32
2 NH C Ph OH 0.2 46.3 232 4.5 43.5. 9.7
3 O Si Ph OH 2.8 909 325 1.1 ND
4 O C Ph F 4.98 457 91 2.0 35.4 17.7
5 NH C Ph F 12.45 >1000 >80 5.3 30.3 5.7
6 O Si i-Pr OH 227.1 >1000 >4.4 >13 25.2
Ph = phenyl, I-Pr = isopropyl.
ND = Not detectable.
IC50 values for standard drugs against P. falciparum: Chloroquine = 0.195 µM; artemisinin = 0.0057 µM.
L-6 cells are rat skeletal myoblasts and compounds are assayed against these cells to give an idea of toxicity against mammalian cells.
Selectivity (Select.) values are shown in parentheses, where:
Selectivity for the enzyme is defined as Ki (human)/Ki (P. falciparum, Pf). Selectivity for the parasite is defined as IC50 (L-6 cells)/IC50
(P. falciparum, Pf).structure activity relationships. A number of changes at
the 5# and 3# positions of the deoxyribose ring pro-
duced informative changes in both inhibition and selec-
tivity (Table 1). The 5# position was varied: by substitut-
ing the nitrogen with an oxygen (1, 3, 4, and 6); the
carbon with a silicon (3 and 6), which is larger and
should allow greater flexibility of the phenyl groups;
and the phenyl groups with isopropyl groups (6), which
should probe the necessity of having aromatic substitu-
ents. The 3# position was varied by replacing the hy-
droxyl with a fluorine (4 and 5). These studies show that
2#deoxyuridine derivatives containing either a triphe-
nylmethyl or triphenylsilyl substituent at the 5# position
of the deoxyribose ring are selective inhibitors of
PfdUTPase (Table 1). The following conclusions can be
drawn: (1) substitution of three alkyl groups for the
three phenyl groups at the 5# position abolishes activity
(compound 6); (2) the central carbon atom of the triphe-
nylmethane group can be replaced by a silicon atom
with little effect on inhibition of the enzyme (comparing
compounds 1 and 3), although the selectivity for the
Plasmodium enzyme is enhanced considerably; (3) re-
placement of the 5# oxygen with a 5# amino group is
also tolerated (comparing compounds 1 and 2 and
compounds 4 and 5); (4) there is some room for varia-
tion at the 3# position as the OH group can be replaced
by a fluorine atom with little effect on activity (compar-
Structure
332To evaluate further dUTPase as a drug target, com- o
Rpounds were screened against P. falciparum K1 strain
mcultured in erythrocytes. It is not possible to make a
ddirect comparison between inhibition of the P. falci-
sparum enzyme and growth inhibition of P. falciparum,
fbecause in cellular systems there are many other
ifactors to take into account including the rate of pene-
ftration of compounds into cells and their metabolic sta-
cbility. However, compounds showing activity against
bthe enzyme also showed activity against the parasite,
tindicating that PfdUTPase inhibitors have the potential
mto inhibit growth of the organism (Table 1). Compounds
lwere also screened against mammalian cells (L-6 cells,
rat myoblasts) to give an indication of selectivity to par-
aasitic over mammalian cells. The compounds gave a
ireasonable degree of selectivity, indicating that the
wmode of action is not a general toxic effect, but some-
mthing more specific.
P
t
Structure of the P. falciparum dUTPase s
Inhibitor Complex c
To investigate the structural basis for the selectivity of r
the trityl deoxyuridine derivatives against the parasite d
enzyme, crystals of PfdUTPase in complex with com- i
pound 4 were grown and analyzed by X-ray crystallog- t
raphy. A summary of data processing and refinement c
statistics is shown in Table 2 and Figure 3A shows the w
Rmerge and I/σI as a function of resolution. During the s
course of the refinement, noncrystallographic restraints 8
were not imposed. However, the model building was f
carried out using averaged maps until a stage was r
reached (Rcryst 22.8 and Rfree 33.2) at which differences p
between the three subunits, particularly at the C termini W
and around the low complexity regions, became obvi- 5
ous. The refinement finally converged with Rcryst and i
Rfree values of 19.6 and 29.6, respectively. This differ- s
ence in R factors is to be expected for a structure of b
Athis resolution (2.4 Å) with weak observations in theTable 2. Crystallographic Data Processing and Refinement Statistics
Data processing statistics
P41 cell dimensions (Å) a = b = 62.83, c = 121.53
Diffraction limits (Å) 40.0–2.40 (2.44–2.40)a
No. unique reflections (Å) 18,324
Completeness of data (%) 99.7 (95.0)
Rmerge (%) 9.8 (66.9)
Multiplicity 4.9 (2.8)
I/σI 15.9 (1.4)
Refinement statistics
Rcryst (%) 19.6
Rfree (%) 29.6
Rms  bond length (1–2) (Å) 0.02 (0.02)b
Rms  angles (°) 1.99 (2.02)
Rms  chiral volumes (Å) 0.12 (0.20)
Structural information, non-hydrogen atoms
No. of atoms: protein, inhibitor, water 3434, 105, 121
Average B (Å2): protein, inhibitor, water 42.4, 36.5, 40.7
Disallowed Ramachandran angles in residue: Ser104
Rms  on Cα: PfdUTPase, mol. A versus. mol. B 0.44
Rms  on Cα: PfdUTPase, mol. A versus mol. C 0.36
Rms  on Cα: PfdUTPase versus Human dUTPase trimer 0.56
a Highest resolution shell statistics given in parentheses.
b Average geometric restraints given in parentheses.uter shell and disordered regions in the molecule.
EFMAC, which is based on maximum likelihood mini-
ization, is well suited to handling the problem of weak
ata and weighting them accordingly. Figure 3B, which
hows Rcryst and Rfree as a function of resolution in the
inal refinement cycle, indicates that R and Rfree do not
ncrease significantly at the 2.4 Å resolution limit. The
inal data precision indicator (DPI) value of 0.32 Å indi-
ates that the errors in the model are higher than would
e expected for a structure which had excellent data
o 2.4 Å. Nevertheless, it is a reliable indicator for the
ost ordered parts of the structure which include the
igand binding sites.
The final model comprises a homotrimer of 429
mino acid residues (82.7% of the actual total), three
nhibitor molecules (one at 50% occupancy), and 121
ater molecules. Those residues absent from the
odel correspond to disordered regions of the PfdUT-
ase trimer, particularly in the LCR (residues 64–79) and
he C termini (residues 156–173). In each of the three
ubunits of the trimer, the polypeptide fold is the same,
onsisting of 13 segments of β strand and two helical
egions (Figure 4A). The strands are arranged in three
iscrete β sheets that pack against one another enclos-
ng a hydrophobic core, representing a variation on the
heme of the jelly roll. Extending from an otherwise
ompact tertiary structure are the C-terminal residues,
hich are invariably disordered in the absence of sub-
trate (Nord et al., 2001), and the LCRs (residues 59–
3) that form loops at the top of the molecule, away
rom the active site (Figure 4A). Where it is possible for
esidues of the LCRs to interact with the rest of the
rotein, they do in fact make very specific contacts.
ithin each subunit the main chain atoms of residues
5–59 hydrogen bond to those of residues 80–84 form-
ng a twisted antiparallel β strand. In two of the three
ubunits the side chain of residue Asn83 hydrogen
onds to the main chain carbonyl group of residue
la110, providing additional intramolecular interactions.
P. falciparum dUTPase as Antimalarial Drug Target
333Figure 3. X-Ray Data and Refinement Sta-
tistics
(A) Data processing statistics for the PfdUT-
Pase 2.4 Å data as a function of resolution
(Rm = Rmerge).
(B) Rcryst and Rfree in the final refinement cy-
cle as a function of resolution.Those residues on the outside of the loop constituting
two thirds of the LCRs are disordered.
Comparison of the PfdUTPase trimer with that of the
human enzyme (representative of the trimeric dUTPase
family [Mol et al., 1996]) reveals a common overall sub-
unit topology and trimer organization (Figures 4A and
4B). However, an unusual difference in folding toward
the C terminus of the Plasmodium enzyme results in a
rearrangement within the trimer. In each subunit of the
human enzyme, the final β strand extends away from
the core of the molecule and is incorporated into a β
sheet of a neighboring subunit (Figure 4B). This 3D do-
main swapping (Schlunegger et al., 1997) doubtless en-
hances trimer stability by increasing the number of in-
tersubunit contacts. In contrast, in the P. falciparum
enzyme, the C-terminal part of the chain executes a
sharp turn and the last β strand packs alongside the
first β strand in the core of the molecule. The redirection
of the chain is facilitated by the presence of residue
Gly144, which takes the place of bulky side chains in the
human and other trimeric dUTPases (Figure 1). As a
result, each folding domain in PfdUTPase is made up ofa single polypeptide chain and many of the intersubunit
interactions involving the C terminus are absent. Com-
pensating intersubunit interactions include a number of
hydrogen bonds between three symmetry-related Ser104
residues, and van der Waals’ packing interactions be-
tween three consecutive tyrosines (residues 62–64 in
the LCR) and residues of a neighboring subunit (His2,
Leu56, Tyr58, Pro146, and Ser148).
Inhibitor Binding
The PfdUTPase trimer contains three identical, solvent-
accessible substrate binding sites, one at each sub-
unit-subunit interface. Three inhibitor molecules (com-
pound 4) were built into the structure individually to
allow for differences in binding, but all three molecules
bound in an identical manner. Two of the inhibitors were
assigned full occupancies (Figure 5) while the third site
was estimated to be only half occupied by the inhibitor.
This site is the most open, i.e., least enclosed by crys-
tal contacts.
Each of the three inhibitor molecules makes an
extensive set of interactions with residues of conserved
Structure
334T
t
F
d
P
r
o
r
c
p
f
s
d
f
p
s
b
T
P
t
P
a
h
D
P
o
t
a
a
l
n
e
p
i
m
d
c
b
Figure 4. Ribbon Diagrams of the P. falciparum and Human dUTPases d
t(A) Ribbon diagram of the PfdUTPase trimer. The three subunit
chains are colored individually and the ordered residues of the c
LCRs on the front face of the trimer are colored yellow. Compound t
4, which is bound at each of the subunit interfaces, is drawn in ball o
and stick with atoms colored according to type (carbon in white,
anitrogen in blue, oxygen in red, and fluorine in green).
t(B) Ribbon diagram of the human dUTPase trimer with the three
csubunit chains colored individually. The exchange of the final β
strand among the subunits is evident. dUDP molecules, which are i
bound at the subunit interfaces, are drawn and colored similarly to i
compound 4 (phosphorus colored cyan). These figures were made b
using MOLSCRIPT (Kraulis, 1991) and Raster3D (Merritt and Ba-
ocon, 1997).
b
s
cmotifs in the protein (Figures 1 and 6). The uracil moiety
forms hydrogen bonds to the side chain of residue b
oAsn103 and the main chain of residue Ile117, and is fur-
ther stabilized by flanking apolar contacts with the side i
ichain of the highly conserved residue Ile108 and one of
the phenyl rings of the trityl group. The deoxyribose t
ring is maintained in position by a parallel ring stacking
interaction with the strongly conserved side chain of fyr112, however, the fluorine atom attached to C3# of
he sugar ring makes no interactions with the protein.
inally, the aromatic rings of the trityl group form van
er Waals interactions with the side chains of residues
he46, Lys96, and Ile117 and the main chain atoms of
esidues 92 and 93.
Comparison of the mode of inhibitor binding with that
f dUDP binding (substrate analog) in human dUTPase
eveals that the uracil base binds very similarly in each
ase, while the deoxyribose ring of compound 4 is dis-
laced to allow the trityl group to interact with a dif-
erent, more hydrophobic part of the substrate binding
ite than that occupied by the diphosphate moiety of
UDP (Figures 7A and 7B). As a result, it is impossible
or residues of motif 5 at the C terminus (which form
art of the substrate binding site only in the presence of
ubstrate or substrate analog) to approach the ligand
inding site, and these residues remain disordered.
his comparison indicates that compound 4 selects for
fdUTPase over human dUTPase by way of the interac-
ions of the trityl group with the side chains of residues
he46 and Ile117, which are equivalent to the smaller
nd less hydrophobic residues Val42 and Gly87 in the
uman enzyme (Figure 1).
iscussion
reviously reported inhibitors of dUTPases are analogs
f deoxyuridine triphosphate, in which the bond be-
ween the α and β phosphate groups is nonhydrolyz-
ble, the oxygen being replaced by an amino (McIntosh
nd Haynes, 1997; Hidalgo-Zarco et al., 2001) or methy-
ene group (Zalud et al., 1995). These compounds are
ot suitable drug candidates as they are chemically and
nzymatically unstable, and their high charge prevents
enetration across membranes. By contrast, these new
nhibitors have chemical properties that make them
ore suitable as drug candidates. In each of them, the
eoxyuridine moiety, for which the enzyme is specifi-
ally adapted, remains intact, however, the “tail” has
een designed to be bulky and hydrophobic and quite
ifferent from the natural substrate. The crystal struc-
ure shows that, while the uracil moiety of these new
ompounds binds in the conserved uracil binding site,
he triphenyl group is able to exploit a nonpolar region
f the substrate binding site (including residues Phe46
nd Ile117) thereby blocking the active site. The struc-
ure also explains some, but not all, of the effects asso-
iated with modifications to the inhibitor (Table 1). For
nstance, it is likely that substitution of phenyl rings for
sopropyl groups has a detrimental effect on both inhi-
ition and selectivity owing to the loss of favorable π
rbital interactions with residue Phe46 and the uracil
ase facilitated by the trityl group. In another case, the
ubstitution of a silicon atom for a carbon atom at the
enter of the triphenyl group may increase separation
etween the phenyl rings, thus allowing the inhibitor to
ptimize the above-mentioned π orbital interactions. It
s less clear why the 3# fluoro group enhances selectiv-
ty since this atom makes no specific interactions with
he protein in the crystal structure.
The protein itself has some very interesting and novel
eatures. Many Plasmodium proteins contain long in-
P. falciparum dUTPase as Antimalarial Drug Target
335Figure 5. Stereoview Illustration Showing the
Atomic Coordinates for the PfdUTPase In-
hibitor Compound 4, with Associated Fo − Fc
Electron Density (Omit Map) Contoured at 3σ
Atoms are colored according to type (carbon
in black, oxygen in red, nitrogen in blue, and
fluorine in green). This figure was made
using BOBSCRIPT (Esnouf, 1997).loops gathered together at the top of the trimer, inde-
Figure 6. Schematic Illustration of the Inhibitor Binding Site in
PfdUTPase
The atoms of the inhibitor compound 4 (Dux 1D) are colored ac-
cording to type and a water molecule is shown as a turquoise
sphere. Residues which interact with the inhibitor, either by way of
hydrogen bonding (dashed lines) or hydrophobic interactions (ra-
dial spokes) are labeled by residue number and subunit identifier
(A or C). This figure was made using LIGPLOT (Wallace et al., 1995).they are not totally without structure and probably con-
Figure 7. Stereoview Illustrations of the Inhibitor Binding Sites in
the P. falciparum and Human dUTPases
(A) The human enzyme (green atoms) is superimposed on the
P. falciparum enzyme (blue atoms) by aligning the uracil moiety of
their respective inhibitors.
(B) Orthogonal view of the inhibitor binding sites in the two en-
zymes, colored as above.sertions known as low complexity regions (LCRs),
which often contain distinctive homopeptide repeats of
hydrophilic amino acid residues. The prevailing wisdom
is that these areas lack order, forming loops between
other secondary structure elements in the protein. Their
function, if any, is not known, although one tenable ar-
gument is that they contribute to immune evasion dur-
ing parasite invasion (Brocchieri, 2001). The LCRs of
PfdUTPase, comprising residues 59 to 83 in each sub-
unit, are a typical case in point. They form three largependent of the main protein fold. They do not interfere
with the essential elements of the protein, namely the
substrate binding site and trimer formation; however,
Structure
336Figure 8. Stereoview Illustration Showing a Superimposition of Three Subunits from a Selection of Different Trimeric dUTPases
P. falciparum in red, human in green, and M. tuberculosis in blue.
Chain termini are labeled N and C, and the beginning and end of the disordered regions of the low-complexity region in PfdUTPase are
indicated by residue number. This figure was made using MOLSCRIPT (Kraulis, 1991).tribute to trimer stability. Their close proximity to the C l
Dtermini would not, on stereochemical grounds, inhibit
the C-terminal domain swapping observed in other tri- t
dmeric dUTPases so it is unlikely that these two features
are linked. a
dA superimposition of one subunit from three of the
trimeric dUTPase crystal structures shows that, despite c
rlow sequence homology in many areas of these pro-
teins, the fold is very well conserved (Figures 1 and 8). w
gThe only significant conformational variation apart from
the C-terminal flip in the Plasmodium enzyme is toward a
athe N terminus, where residues 8–19 in the human en-
zyme and their equivalents in the other structures form a
Pa variety of distorted β strands. In PfdUTPase this seg-
ment contains four additional residues and forms a
Eshort α helix. Such variations in conformation are of
little consequence to the enzyme since they occur on E
the outside surface of the trimer where evolutionary re- C
straints connected with substrate recognition and tri- q
fmer formation are at their lowest. On the other hand, a
ctwo-residue insertion after residue 103 in PfdUTPase
uplaces residue Ser104 at the heart of the trimer, where
Tits hydrogen bonding capability is used to maximum
C
effect in stabilizing the trimer. This feature is also seen B
in the trimeric dUTPase from M. tuberculosis (acces- s
(sion code 1mq7), and a similar insertion in the E. coli
enzyme results in van der Waals interactions between
Bthree symmetry-related Leu85 side chains.
eAs more information is gathered about dUTPases re-
w
garding structure and function, so these enzymes, with m
their essential cellular activities, are being recognized T
bfor their potential as drug targets against a range of
ldiseases (McIntosh and Haynes, 1997; Hidalgo-Zarco
4and Gonzalez-Pacanowska, 2001). The present study
efocuses on the dUTPase from P. falciparum as a candi-
c
date target for drugs directed against the most severe p
form of malaria. We have demonstrated that expression (
oof the enzyme occurs throughout the parasite in theate trophozoite and schizont stages coinciding with
NA replication, and have discovered a series of selec-
ive inhibitors whose chemical properties give them
rug-like properties. These compounds also exhibit
ntiparasite activity, making them viable leads for drug
evelopment. The crystal structure of PfdUTPase in
omplex with one of these inhibitors explains the gene-
al mode of inhibition as well as the basis for selectivity,
hich derives from the combined bulk of the trityl
roup and the more subtle hydrogen bonding inter-
ctions of the uracil base. This structure will serve as
template for further rounds of drug development
imed at increasing inhibition of, and selectivity for,
fdUTPase.
xperimental Procedures
xpression and Purification of PfdUTPase
onserved motifs of the human dUTPase enzyme were used as a
uery to identify the Pfdut gene in the sequence of the Plasmodium
alciparum 3D7 strain held in the www.tigr.org database. The entire
oding sequence was amplified by PCR from a template cDNA
sing the oligonucleotides ATG-PFdut (CATATGCATTTAAAAATTG
ATGTCTG) and TGA-PFdut (GGATCC-TCAATATTTATTATCGATGT
GATC). These primers were designed to introduce NdeI and
amHI restriction sites at the 5# and 3# ends of the Pfdut coding
equence for convenient cloning in the expression vector pET11
Stratagene).
Recombinant P. falciparum dUTPase was expressed in E. coli
L21 (DE3) cells which had been transformed with the pET11Pfdut
xpression vector. Cell pellets from a two liter IPTG-induced culture
ere resuspended in 40 ml of 20 mM sodium acetate (pH 5.5), 50
M NaCl, 5 mM MgCl2, 1 mM DTT (buffer A), and 20 M PMSF.
he cells were lysed by sonication, and the cell extract was cleared
y centrifugation at 15,000 rpm for 45 min. The supernatant was
oaded onto a 50 ml phosphocellulose (Whatman P-11) column at
°C and eluted with a 50 mM, 2 M NaCl gradient in buffer A. The
nzyme was then dialyzed against buffer A, prior to gel filtration
hromatography on a 120 ml Superdex 75 column at 4°C. As a final
urification step, the enzyme was dialyzed against 20 mM Tris-HCl
pH 8.5), 20 mM NaCl, 5 mM MgCl2, and 1 mM DTT and loaded
nto a Mono Q column at room temperature. The column was de-
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337veloped with a 20 mM, 1 M NaCl gradient giving dUTPase of ap-
proximately 98% purity.
Enzyme Inhibition Assays
The preparation of inhibitor compounds used for the inhibition as-
says will be described elsewhere. Nucleotide hydrolysis was moni-
tored by mixing enzyme and substrate with a rapid kinetic acces-
sory (Hi-Tech Scientific) attached to a spectrophotometer (Cary 50)
and connected to a computer for data acquisition and storage as
described (Hidalgo-Zarco and Gonzalez-Pacanowska, 2001). Pro-
tons, released through the hydrolysis of nucleotides, were neutral-
ized by a pH indicator in weak buffered medium with similar pKa
and monitored spectrophotometrically at the absorbance peak of
the basic form of the indicator. The ratio between the indicator and
the buffer concentration was 50:2500 (M) and the absorbance
changes were kept within 0.1 units. The indicator/buffer pair used
was bromocresol purple/MES (pH 5.7–6.2, 605 nm). Assay mixes
contained 30 nM of PfdUTPase, 50 M dUTP, 5mM MgCl2 and 2.5
mM DTT, 1.25 mg/ml BSA, and 100 mM KCl. Vmax and KMapp were
calculated by fitting the resulting data to the integrated Michaelis-
Menten equation. The apparent KM values were plotted against in-
hibitor concentration, and Ki values (Table 1) were obtained accord-
ing to Equation 1:
KMapp =
KM
Ki
[I] + KM (1)
Indirect Immunoflourescence Microscopy
Anti-PfdUTPase antibodies were raised in rabbits. These identified
a single band in parasite lysates resolved by SDS polyacrylamide
gel electrophoresis in Western blotting experiments. For indirect
immunofluorescence microscopy, cultures of P. falciparum-
infected red blood cells with approximately 20% parasitaemia were
used. Cells were allowed to adhere to ethanol-treated coverslips,
treated with cold acetone (Merck) for 5 min, and rehydrated with
PBS (pH 8.0). Subsequently, they were blocked with 0.5% BSA in
PBS (pH 8.0) for 1 hr and incubated with the polyclonal anti-PfdUT-
Pase antibody diluted 1:100 in blocking buffer for 1 hr at room tem-
perature. After three 5 min washes with blocking buffer, cells were
incubated in the dark with diluted 1:500 goat anti-rabbit IgG FITC-
conjugate (Sigma) for 1 hr. After five washes in the dark with block-
ing buffer at room temperature, the parasite preparation was dried
and incubated with Vectashield (Vector Laboratories) and propid-
ium iodide, and analyzed on an Axiophot Zeiss microscope. Pro-
pidium iodide specifically stains nuclei allowing detection of para-
sitized red blood cells.
Assays were carried out against P. falciparum K1 strain cultured
in human red blood cells as described elsewhere (Jones et al.,
2004).
Protein Crystallization and X-Ray Data Collection
Crystals were obtained using a protein solution consisting of
PfdUTPase at 10 mg ml−1 with a 3-fold molar excess of the inhibi-
tor, compound 4 (Table 1). The crystals grew at 18°C by hanging
drop vapor diffusion against a reservoir solution containing 0.1 M
HEPES (pH 7.1), 0.8 M sodium methanoate, 25% w/w polyethylene
glycol 2000 monomethyl ether (PEG-MME 2000, originating from
CSS I screen, Brzozowski and Walton, 2001). Preliminary character-
ization revealed that the PfdUTPase crystals belong to space group
P41 or P43 corresponding to one PfdUTPase trimer in the asymmet-
ric unit and a solvent content of 40%. Subsequently, a crystal of
dimensions 0.05 × 0.01 × 0.01 mm3 was vitrified at 120 K in a cryo-
protectant solution (0.8 M sodium methanoate, 35% w/w PEG-
MME 2000), prior to data collection on station ID14-4 at the ESRF,
Grenoble, France, using an ADSC CCD detector. The data, extend-
ing to 2.4 Å, were processed using DENZO and SCALEPACK Ver-
sion 1.97.2 (Otwinowski and Minor, 1997).
Structure Solution and Refinement
Trimeric dUTPase crystal structures from several different species
(E. coli, EIAV, FIV, M. tuberculosis) were tried as molecular replace-
ment models for rotation and translation function calculations im-
plemented in both the AMoRe (Navaza, 1994) and MOLREP (Vaginand Teplyakov, 1997) packages. The M. tuberculosis dUTPase tri-
mer, generated using the coordinate set 1mq7, which shares 30%
identity with P. falciparum dUTPase, proved to be the only model
that could satisfactorily distinguish the correct space group (P41)
from its enantiomorph, (P43) (correlation coefficients of 33.8% and
30.4%, respectively) and provide a distinctive, high scoring rotation
and translation solution. Confidence in this solution increased
when it was observed to be a common, although less distinctive,
entry in the lists of solutions obtained using the other models.
Refinement of the structure was carried out using maximum like-
lihood minimization implemented in REFMAC (Murshudov et al.,
1997), 5% of the total data being excluded from the refinement
for the purpose of R free calculations. After some initial cycles of
refinement, 2Fo − Fc and Fo − Fc electron density maps were calcu-
lated and examined but these proved difficult to interpret. Three-
fold noncrystallographic symmetry averaging and density modifi-
cation with DM (Cowtan and Zhang, 1999) greatly improved the
quality of the maps resulting in unambiguous electron density fea-
tures to guide the introduction of the P. falciparum sequence in the
better-defined regions of the structure. With subsequent refine-
ment and model building using the XFIT routines in QUANTA (Ac-
celrys) (Oldfield, 2001), differences between the three subunits of
the dUTPase asymmetric unit emerged, and each was then built
independently, using 2Fo − Fc and Fo − Fc electron density maps.
Electron density indicating the presence of the inhibitor appeared
in each of the three substrate binding sites, and three inhibitor
molecules were built into the structure.
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